
James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.

Your AI-Trained Oncology Knowledge Connection!


Published: September 15th 2015 | Updated: